Profiles people listing in a scrolling container.
  1. Home
  2. People

Marcus Noyes, OD, FAAO, FSLS

Clinical Assistant Professor of Ophthalmology and Visual Sciences

Current Positions

  • Clinical Assistant Professor of Ophthalmology and Visual Sciences

Education

  • BA in Biochemistry, University of Northern Iowa, Cedar Falls, IA
  • Resident (Optometry)-The Ohio State University Wexner Medical Center, Havener Eye Institute, Columbus, OH
  • Fellow in Optometry, American Academy of Optometry, Orlando, FL
  • Fellow in Optometry, Scleral Lens Society

Research Interests

  • A Multicenter, Randomized, Placebo-Controlled, Phase 3 study on the Safety and Efficacy of Deflazacort (EMFLAZA) in Subjects with Limb-Girdle Muscular Dystrophy, Sponsor: PTC Therapeutics, Inc; Dept: Ped Neuro/Muscular. Procedures: Visual Acuity, tonometry, dilated eye exam, direct Ophthalmoscopy (direct/indirect); asses for cataracts. **Closed out** 9/10/16-2/23/21.
  • Protocol 18F-MC-GPGL: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide (LY3298176) versus Metformin in Patients with Type 2 Diabetes. Sponsor: Eli Lily and Co. Dept: Preventive Medicine/Epidemiology. Procedures: Dilated funduscopic exam R/O PDR/DM/NPDR- screen only **Closed out** 9/19-2/21
  • Protocol 15F-MC-GPGM (a): Efficacy and Safety of LY3298176 (Tirzepatide) Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes. Sponsor: Eli Lilly and Co. Dept: Preventative Medicine/Epidemiology. Procedures: Dilated funduscopic exam R/O PDR/DM/NPDR screen only **Close out** 9/19-2/21
  • Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety of TOL-3021 for Diabetes Autoimmunity Withdrawn in New Onset and in Established Patients (SUNRISE). Sponsor: Tolerion, Inc. Dept: Ped Endocrine. Procedure: Fundus exam and photos. Study halted. 12/20- 11/20
  • Protocol 15F-MC-GPGN (a): Phase 3-The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes. Sponsor: Eli Lilly and Co. Dept: Preventative Medicine/Epidemiology. Procedures: Dilated fundoscopic exam performed by an eye care professional. 3/21-present.
  • A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease. Sponsor: NIH. Dept: Neurology. Procedures: Exam to assess for glaucoma/cataracts; no dilation contraindicated due to therapy. 10/20-present.
  • Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG INF-ALFA-2A for 48 weeks Compared with PEG-INF-ALPA-2A Monotherapy and Placebo Treatment in Patients Chronically infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleoside Therapy (D-LIVR). Sponsor: EigerBioPharmaceuticals, Inc. Dept: Gastroenterology. Procedures: BCVA, automated threshold perimetry HVF, SD-OCT, dilated SLE 11/20-presnet.
  • Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients with Cerebrotendinous Xanthomatosis. Sponsor: Retrophon. Procedures: Exam includes BCVA and cataracts. Dates pending.
  • Phase IIb Multi-Center, Randomized, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together). Sponsor: GlaxoSmithKline. Dept: GI/Hepatology. Procedures: Standard of care eye exam. Dates pending.
  • Multicenter Data Collection for Scleral Lens Outcomes 4/21-present

Licenses & Certifications

  • Iowa License, Optometry

Selected Publications